Protocol Ledger

NCT04910685 · Phase II/III · RECRUITING

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

Interventional Phase II/III clinical trial protocol NCT04910685 sponsored by Blueprint Medicines in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-11-30 Enrollment: 534 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04910685
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)534 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04910685
Protocol FieldVerified Registry Value
NCT IdentifierNCT04910685
Consolidated Lead SponsorBlueprint Medicines
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment534 participants (ESTIMATED)
Registered Start Date2021-11-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI